US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Interim report January – September 2012

    Continued strong growth and resolution to distribute TransplantationThird quarterGroup, including discontinuing operations · Sales growth was 17 percent in local currency. Sales amounted to SEK 97 (85) million, corresponding to an increase of 14 percent in SEK. · Sales growth within Fertility was 16 percent in local currency and 13 percent in SEK. Sales growth within Transplantation was 23 percent in local currency and 22 percent in SEK. · Operating income (EBIT) amounted to SEK 13 (14) million. One-time expenses of SEK 5 million were charged against operating income ahead of

    All patients included in the clinical study on STEEN Solution™ in the USA

    In the clinical study that was begun during 2011 on STEEN Solution™ with the aim of forming a basis for sales approval in the USA, a total of 13 patients have now received transplants. The required number of patients, which was 12, has thereby been included in the study. “Even if some work remains and it is difficult to assess how the FDA will reply it is now reasonable to assume that this is a big step closer to sales approval in the most important market in the world,” says Dr Magnus Nilsson, who is responsible for Vitrolife’s transplantation area.Since autumn 2011 Vitrolife has run a

    Xvivo to be a more independent unit within Vitrolife

    Vitrolife’s subsidiary Xvivo, with business activities within the organ transplant area, is in an intensive and exciting development phase which now requires greater focus, and will thus become a more independent unit within the Vitrolife Group. Vitrolife’s former CEO Magnus Nilsson will, as the CEO of Xvivo, be able to focus entirely on this line of business. The Board intends to propose to the shareholders that Magnus be given the opportunity to buy into the company and become the owner of approximately 15% of Xvivo. Xvivo will also have an external Board.As was announced on October 31,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe